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Background.  Switching antiretroviral therapy (ART) in people with HIV (PWH) can influence their risk for drug–drug inter-
actions (DDIs). The purpose of this study was to assess changes in the incidence and severity of DDIs among PWH who switched 
their ART to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Methods.  This was a multicenter retrospective cohort study of PWH on ART and at least 1 concomitant medication (CM) 
who switched to BIC/FTC/TAF between 3/2018 and 6/2019. Using the University of Liverpool’s HIV Drug Interaction Database, 2 
DDI analyses were performed for each patient. The first assessed patients’ preswitch ART regimens with their CM list. The second 
assessed the same CM list with BIC/FTC/TAF. Each ART-CM combination was given a score of 0 (no or potential weak interaction), 
1 (potential interaction), or 2 (contraindicated interaction). A paired t test analyzed changes in total DDI scores following ART 
switches, and linear regression examined factors contributing to DDI score reductions.
Results.  Among 411 patients, 236 (57%) had at least 1 DDI present at baseline. On average, baseline DDI scores (SD) were 1.4 
(1.8) and decreased by 1 point (95% CI, –1.1 to –0.8) after patients switched to BIC/FTC/TAF (P < .0001). After adjusting for demo-
graphics, baseline ART, and CM categories, switching to BIC/FTC/TAF led to significant DDI score reductions in patients receiving 
CMs for cardiovascular disease, neurologic/psychiatric disorders, chronic pain, inflammation, gastrointestinal/urologic conditions, 
and conditions requiring hormonal therapy.
Conclusions.  Treatment-experienced PWH eligible to switch their ART may experience significant declines in number and 
severity of DDIs if switched to BIC/FTC/TAF.
Keywords.  ART; bictegravir; drug interactions; HIV; switch.
People with HIV (PWH) often have or develop other chronic 
medical conditions as they age and receive multiple medica-
tions in addition to their antiretroviral therapy (ART) [1]. This 
increases their risk for polypharmacy and its complications, 
including medication nonadherence, HIV treatment failure, 
adverse drug events, and drug–drug interactions (DDIs) [2–6]. 
In virally suppressed treatment-experienced PWH, switching 
ART can simplify treatment, improve tolerability, and limit 
long-term toxicity. It can also influence the presence of DDIs in 
those receiving concomitant medications (CMs) [7–9].
Given their efficacy, safety, and tolerability, integrase inhib-
itor–based regimens are preferred therapy options and are com-
monly used to simplify ART in treatment-experienced patients 
[9–11]. Among the integrase inhibitors, bictegravir has few 
DDIs and is available in a single-tablet regimen with tenofovir 
alafenamide and emtricitabine (BIC/FTC/TAF) [12]. The ex-
tent to which switching ART to BIC/FTC/TAF can influence 
the presence of DDIs in treatment-experienced PWH is unclear. 
The purpose of this study was to assess changes in the incidence 
and severity of DDIs after switching to BIC/FTC/TAF.
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METHODS
This was a multicenter retrospective cohort study of adult 
PWH on ART and at least 1 CM who switched to BIC/FTC/
TAF between 3/2018 and 6/2019 in the outpatient setting. 
Demographic data including age, sex, and race were extracted 
from medical records of eligible patients, along with their 
medications, duration of HIV infection, duration of ART, 
number of previous ART regimens, preswitch HIV RNA, and 
their reason for switching to BIC/FTC/TAF. Institutional re-
view board approval was obtained before data collection at 
each study center.
To assess the incidence and severity of DDIs with CMs before 
and after each patient’s switch to BIC/FTC/TAF, the University 
of Liverpool’s HIV Drug Interaction Database was used [13]. 
Two DDI analyses were performed for each patient. The first as-
sessed a patient’s preswitch ART regimen with the list of active 
medications located in their electronic medical record on the 
day they switched their ART. The second assessed the same CM 
list with BIC/FTC/TAF. Each ART-CM combination was given 
a numerical score that corresponded to the DDI categories 
listed in the University of Liverpool database. These were scores 
of 0 (no or potential weak interaction), 1 (potential interaction), 
or 2 (contraindicated interaction). Total DDI scores for each 
patient, both before and after switching to BIC/FTC/TAF, were 
then calculated.
A paired t test was used to analyze changes in DDI scores 
following ART switches, and a linear regression model was 
used to examine factors contributing to DDI score reductions. 
In addition, McNemar’s test was used to analyze changes in 
the proportion of patients with at least 1 DDI before and after 
switching to BIC/FTC/TAF. Covariates in the regression model 
included patient demographics, viral suppression status, and 
baseline ART. To analyze the influence of CMs in the regression 
model, each medication was placed into 1 of the following 
categories according to its therapeutic indication: cardiovas-
cular, antihyperglycemic, anti-inflammatory, anti-infective, 
chronic pain, neurologic/psychiatric, gastrointestinal/urologic, 
hormonal therapy, or polyvalent supplements (Table 1). All sta-
tistical analyses were performed with SAS 9.4 (SAS Institute 
Inc., Cary, NC, USA) at a significance level of .05.
RESULTS
A total of 411 patients met study criteria and were included in 
the analysis (Table  2). The majority were African American 
(70.6%) and male (61.6%), with a mean age of 51 years. Patients 
had been living with HIV and receiving ART for a median of 
14 and 10 years, respectively. The majority were receiving re-
gimens containing either dolutegravir (37%) or elvitegravir 
(29.4%) plus 2 nucleoside reverse transcriptase inhibitors before 
switching to BIC/FTC/TAF. Most were also receiving at least 5 
CMs (56.9%). The most common baseline NRTI combinations 
were tenofovir disoproxil fumarate or TAF plus FTC (72%) and 
abacavir plus lamivudine (26%). The most commonly docu-
mented reasons for switching to BIC/FTC/TAF were to improve 
long-term safety (23.6%), reduce regimen complexity (16.8%), 
and mitigate DDIs (14.1%).
Of the 411 patients analyzed, 236 (57%) had at least 1 of the 
552 DDIs identified at baseline. The majority of baseline DDIs 
had scores of 1 (497/552, 90%). Those with scores of 2 (55/552, 
10%) were most commonly the result of pharmacokinetic 
“boosting” agents combined with either corticosteroids (30/55, 
54.5%), quetiapine (7/55, 12.7%), clopidogrel (5/55, 9.1%), or 
direct oral anticoagulants (3/55, 5.5%). Rilpivirine used in com-
bination with proton pump inhibitors (7/55, 12.7%) was also 
common. After switching to BIC/FTC/TAF, only 136/411 (33%) 
Table 1.  Concomitant Medications of Study Participants and Their Corresponding Categories
Cardiovascular Apixaban, amiodarone, amlodipine, atenolol, atorvastatin, clopidogrel, diltiazem, digoxin, eltrombopag, 
hydralazine, metoprolol, nifedipine, pravastatin, rivaroxaban, rosuvastatin, simvastatin, sotolol, 
vorapaxar, valsartan, verapamil, warfarin
Antihyperglycemic Glipizide, metformin, liraglutide, sitagliptin
Anti-inflammatory Aspirin, budesonide (inhaled/nasal), celecoxib, ciclesonide (nasal), dexamethasone (systemic), diclofenac, 
fluticasone (inhaled/nasal), hydrocortisone oral, ibuprofen, meloxicam, mometasone (inhaled/nasal), 
methylprednisolone (injections), naproxen, prednisone (systemic), triamcinolone (inhaled/nasal)
Chronic pain Fentanyl, hydrocodone, morphine, lidocaine, oxycodone, tizanidine 
Anti-infective Acyclovir, atovaquone, clindamycin, doxycycline, fluconazole, itraconazole, ketoconazole, trimethoprim/
sulfamethoxazole, voriconazole, valacyclovir
Hormonal therapy Calcifediol, cholecalciferol, estradiol injection, ethinyl estradiol (oral), ethinyl estradiol/norelgestromin 
(transdermal), norgestimate (oral), levothyroxine, testosterone 
Neurologic/psychiatric Alprazolam, amitriptyline, aripiprazole, bupropion, buspirone, clonazepam, diazepam, divalproex, 
escitalopram, fluoxetine, lurasidone, mirtazapine, nortriptyline, paroxetine, phenytoin, quetiapine, 
risperidone, sertraline, topiramate, trazodone, valproic acid, zolpidem
Gastrointestinal/urologic Alfuzosin, antacids, finasteride, loperamide, omeprazole, pantoprazole, ranitidine, sildenafil, tamsulosin, 
tadalafil
Polyvalent cation supplements Multivitamins, calcium supplements, iron supplements
Other Hydroxyzine, methamphetamine, salmeterol
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Table 2.  Descriptive Summary of Baseline Characteristics (n = 411)
All (n = 411)
Site, No. (%) University of Maryland, Baltimore 100 (24.3)
Thomas Jefferson University Hospital 95 (23.1)
The Brooklyn Hospital 61 (14.8)
Indiana University LifeCare 60 (14.6)
University of Illinois at Chicago 40 (9.7)
Memorial Healthcare System 35 (8.5)
University of California, San Francisco 20 (4.9)
Age, mean (SD)  51.3 (12.4)
Gender, No. (%) Male 253 (61.6)
Female 151 (36.7)
Transgender female 7 (1.7)




Native Hawaiian/Other Pacific Islander 2 (0.5)
No. of years with HIV diagnosis, median (Q1, Q3)a  14.0 (8.0, 22.0)
Total No. of years on ART, median (Q1, Q3)b  10.0 (6.0, 15.0)
No. of previous ART regimens, No. (%)c 1–3 214 (52.1)
4–6 60 (14.6)
≥7 11 (2.7)
Viral suppression (HIV RNA <200 copies/mL), No. (%)d Yes 324 (78.8)
No 52 (12.7)
Switch reason, No. (%)e Long-term safety 97 (23.6)
Complexity 69 (16.8)
Other 66 (16.1)
Drug interactions 58 (14.1)
Side effects 45 (10.9)
Not documented 36 (8.8)
Toxicity 14 (3.4)
Virologic failure 5 (1.2)
Cost 2 (0.5)
Polypharmacy (≥5 concomitant medications), No. (%) Yes 234 (56.9)
No 177 (43.1)
No. of concomitant medications, median (Q1, Q3)  5.0 (3.0, 9.0)






Baseline ART regimen, No. (%) Dolutegravir plus 2 NRTIs 152 (37)
Elvitegravir/cobicistat plus 2 NRTIs 121 (29.4)
Boosted PI plus 2 NRTIs 59 (14.4)
Efavirenz plus 2 NRTIs 34 (8.3)
Rilpivirine plus 2 NRTIs 29 (7.1)
Nevirapine plus 2 NRTIs 4 (1.0)
Dolutegravir plus a boosted PI and 2 NRTIs 4 (1.0)
Dolutegravir plus rilpivirine 3 (0.7)
Elvitegravir/cobicistat plus a PI and 2 NRTIs 2 (0.5)
3 NRTIs 2 (0.5)
Etravirine plus a boosted PI and 2 NRTIs 1 (0.2)
Abbreviations: ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. 
aData not available for 51 subjects. 
bData not available for 144 subjects. 
cData not available for 126 subjects. 
dData not available for 35 subjects. 
eData not available for 19 subjects.
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patients continued to have at least 1 DDI (P < .0001). Declines 
in DDIs were observed for nearly all CM categories (Figure 1). 
The total number of DDIs declined to 188, almost all of which 
had a score of 1 (187/188, 99.5%); these were most commonly 
the result of BIC/FTC/TAF used in combination with either 
polyvalent cation supplements (125/188, 66.5%) or metformin 
(45/188, 23.9%).
In terms of total DDI scores, patients had a median score (in-
terquartile range) of 1 (0–2) or an average (SD) of 1.4 (1.8) at 
baseline and experienced a 1-point reduction (95% CI, –1.1 to 
–0.8) after switching to BIC/FTC/TAF (P <  .0001). In the re-
gression model, DDI score reductions were not associated with 
patient demographics, viral suppression status, or baseline ART, 
but were significantly associated with patient CMs (Table 3). For 
instance, patients receiving cardiovascular medications experi-
enced an average DDI score reduction of 1.42 (95% CI, –1.64 
to –1.19; P  <  .0001) after switching to BIC/FTC/TAF. Similar 
score reductions were associated with neurologic/psychiatric 
medications, gastrointestinal/urologic medications, hormonal 
therapies, and medications for chronic pain. The largest score 
reductions were associated with anti-inflammatory medications 
(–1.9; 95% CI, –2.14 to –1.65; P <  .0001). The only CMs that 
were not associated with DDI score reductions were polyvalent 
cation supplements and medications for diabetes.
Table 3.  Linear Regression for the Difference of DI Scores (Post–Pre; n = 376a)
Variable Estimate 95% CI P Value
Intercept (ref: age 51 y and Black/AA) 0.38 (0.01 to 0.75) .05
Age (per year) 0.00 (0.00 to 0.01) .13
White –0.17 (–0.36 to 0.02) .08
Other race (Hispanic/Latino, Asian, Native Hawaiian/other Pacific Islander) 0.05 (–0.18 to 0.29) .66
Viral suppression (yes) –0.17 (–0.38 to 0.04) .11
Dolutegravir-based ART (yes) –0.18 (–0.50 to 0.15) .28
Elvitegravir-based ART (yes) 0.00 (–0.34 to 0.34) .00
NNRTI-based ART (yes) 0.23 (–0.11 to 0.57) .19
PI-based ART (yes) –0.03 (–0.37 to 0.32) .89
Interactions between the patient’s ART and cardiovascular medications at baseline (yes) –1.42 (–1.64 to –1.19) <.0001
Interactions between the patient’s ART and hyperglycemic medications at baseline (yes) 0.02 (–0.23 to 0.28) .85
Interactions between the patient’s ART and anti-inflammatory medications at baseline (yes) –1.90 (–2.14 to –1.65) <.0001
Interactions between the patient’s ART and pain medications at baseline (yes) –1.49 (–1.85 to –1.13) <.0001
Interactions between the patient’s ART and anti-infectives at baseline (yes) –1.05 (–1.38 to –0.72) <.0001
Interactions between the patient’s ART and hormonal therapies at baseline (yes) –0.82 (–1.16 to –0.48) <.0001
Interactions between the patient’s ART and neurologic and psychiatric medications at baseline (yes) –1.52 (–1.72 to –1.32) <.0001
Interactions between the patient’s ART and gastrointestinal and urologic medications at baseline (yes) –1.51 (–1.79 to –1.24) <.0001
Interactions between the patient’s ART and polyvalent supplements at baseline (yes) –0.02 (–0.21 to 0.17) .82
Interactions between the patient’s ART and other medications at baseline (yes) –0.86 (–1.27 to –0.45) <.0001
Abbreviations: ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
P < .05 is considered significant.




























Figure 1.  Subjects with at least 1 DDI between their ART and selected CM categories pre- and postswitch. Abbreviations: ART, antiretroviral therapy; CM, concomitant 
medication; DDI, drug–drug interaction; GI, gastrointestinal.
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DISCUSSION
We observed significant declines in the incidence and se-
verity of DDIs among treatment-experienced PWH who 
switched their ART to BIC/FTC/TAF. Importantly, these 
declines were significantly associated with a patient’s CMs 
rather than their demographics, viral suppression status, 
or baseline ART. DDI declines also occurred among CMs 
representing a broad range of comorbid conditions. This is 
important because PWH have a disproportionate risk for 
developing multiple medical conditions, experiencing poly-
pharmacy, and incurring DDIs [1–6, 14].
The majority of subjects in this study were experiencing 
polypharmacy and receiving CMs for conditions common to 
patients aging with HIV [15]. These included cardiovascular 
disease, chronic pain, gastrointestinal diseases, and urologic 
disorders. Consistent with prior studies, CMs for these condi-
tions were common sources of DDIs for patients at baseline in 
our study [14, 16, 17]. DDI declines were associated with CMs 
in these medication categories when patients switched to BIC/
FTC/TAF. These DDI declines might have been more substan-
tial in an elderly patient population, because as age progresses, 
polypharmacy and drug interactions among PWH increase sub-
stantially [14]. In addition, patients in this study were also fre-
quently receiving CMs for conditions common to all PWH such 
as neurologic disease, psychiatric illness, co-infections, and con-
ditions requiring hormonal therapy. When patients switched to 
BIC/FTC/TAF, DDI declines were also associated with CMs in 
these medication categories. The only CM categories not asso-
ciated with DDI declines were diabetes and polyvalent cation 
supplements. This finding may have been expected, as most 
subjects were on dolutegravir or elvitegravir at baseline, which 
also interact with metformin and supplements containing poly-
valent cations. Overall, these findings suggest that if patients are 
able to switch their ART to BIC/FTC/TAF, they may experience 
significant declines in DDIs when they are also receiving CMs 
for medical conditions common to all PWH.
In terms of DDI severity, corticosteroids were the most 
common source of contraindicated DDIs for patients at base-
line. These interactions were the result of corticosteroids used 
in combination with pharmacokinetic boosting agents such 
as ritonavir and cobicistat. Pharmacokinetic boosting agents 
are strong cytochrome P450 inhibitors that can elevate corti-
costeroid concentrations, leading to adrenal suppression and 
Cushing’s syndrome [18]. Boosting agents also led to contra-
indicated DDIs in this study with certain antithrombotic and 
antipsychotic medications by inhibiting their cytochrome P450 
metabolism. In prior studies, these types of contraindicated 
interactions increased a person’s risk for experiencing signif-
icant toxicity requiring hospitalization [19, 20]. Because BIC/
FTC/TAF is an unboosted regimen, switching not only reduced 
the total number of DDIs for patients in this study, but also 
removed nearly all contraindicated DDIs that may otherwise 
have resulted in patient harm.
The low incidence of contraindicated DDIs with BIC/FTC/
TAF was also recently demonstrated in a study of nearly 5000 
German PWH [21]. Investigators in this study also utilized the 
University of Liverpool Drug Interaction Database to evaluate 
potential DDIs among patients receiving BIC/FTC/TAF and at 
least 1 CM. Overall, the incidence of DDIs was low, with sev-
eral common medication classes posing no risk for DDIs with 
BIC/FTC/TAF including anti-ulcerants, antirheumatics, and 
lipid-lowering agents. Similar to our study, contraindicated 
combinations with BIC/FTC/TAF in the German cohort were 
rare (<0.25%) and the result of metabolism-inducing medi-
cines such as carbamazepine, oxcarbazepine, and rifampicin 
in the German cohort and phenytoin in our analysis. Overall, 
both studies demonstrate that there is a low potential for DDIs 
between BIC/FTC/TAF and CMs including contraindicated 
combinations. Unique to our study, however, is the finding 
that a substantial number of DDIs can be avoided and contra-
indicated combinations can be nearly eliminated if treatment-
experienced patients can switch their ART to BIC/FTC/TAF 
from their current regimen.
Current treatment guidelines recommend switching a 
patient’s ART regimen when feasible in order to mitigate DDIs, 
as well as reduce treatment complexity, improve tolerability, 
limit long-term toxicity, and reduce costs [7–9]. However, it 
should be noted that switching ART can also lead to new ad-
verse events and even virologic breakthrough in treatment-
experienced patients. Furthermore, switching to or from a 
boosted ART regimen may require dosing adjustments for a 
patient’s CMs. Some subjects in this study were switched to mit-
igate DDIs; however, the majority switched for other reasons 
including safety, tolerability, and regimen simplification. While 
prior studies have demonstrated that regimen simplification 
can reduce a patient’s risk for DDIs, the results of this study sug-
gest that DDI reductions may occur regardless of the reasons for 
switching a patient’s regimen [22].
This study has several limitations. First, our analysis only in-
cluded patients who switched to BIC/FTC/TAF. However, it 
should be noted that BIC and dolutegravir have nearly identical 
drug interaction profiles, and similar DDI reductions would have 
occurred if patients in this study had switched their baseline re-
gimens to dolutegravir/FTC/TAF. Moreover, there are specific 
DDI situations when a dolutegravir-based regimen may be pre-
ferred to BIC/FTC/TAF (ie, concomitant rifamycins) that were 
not captured in this study. Second, our assessment of DDIs using 
the University of Liverpool’s HIV Drug Interaction Database is 
only reflective of the study’s time period. Changes in the tool’s 
identification and assessment of DDI severity since this study 
was conducted are possible. Furthermore, the clinical relevance 
of each DDI identified in this study was not evaluated by the 
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investigators, and it is possible that separate DDIs with the same 
scores could differ considerably in their clinical relevance. Also, 
as a retrospective cohort study, we relied on the accuracy and 
completeness of medical records, but omissions or inaccuracies 
could have influenced the results. For example, we were unable to 
collect patients’ nonprescription medications consistently, which 
may have resulted in an underestimation of DDIs. We were also 
unable to assess patient adherence to CMs, which may have re-
sulted in an overestimation of DDIs. We also placed CMs into 
groups for our analysis, which limited our ability to investigate 
DDI changes for individual CMs following switches to BIC/FTC/
TAF. In addition, dosing adjustments made to offset DDIs were 
not considered within our analysis. Lastly, our cohort was pre-
dominantly African American and male from large, academic, 
and urban medical centers in the United States. As a result, the 
findings may not be generalizable to patients living in rural set-
tings or those living outside of the United States.
CONCLUSIONS
Treatment-experienced PWH who are receiving CMs and are 
eligible to switch their ART may experience significant declines 
in the number and severity of DDIs if their regimen is switched 
to BIC/FTC/TAF. This may be particularly important for pa-
tients experiencing polypharmacy and those receiving CMs for 
conditions common to patients aging with HIV.
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